"instanceType","rationale","description","name","label","uuid:ID","id"
"StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","Study Design 1","","4ed31f70-1371-4d43-98d7-c2bd5e211f31","StudyDesign_1"
